Reclaiming women’s progress post-pandemic
Clinical Portfolio and Pipeline

What's next

At Adaptive, we’re investing in the continued development of immune medicine products, which add new meaning to the stories every patient’s immune system has to tell.

Clinical Portfolio and Pipeline

Diagnostics
SIGNAL
DISCOVERY
CLINICAL
VALIDATION
FDA
SUBMISSION
FDA
CLEARANCE
MONITOR MRD
Logo for clonoSEQ
SIGNAL
DISCOVERY
CLINICAL
VALIDATION
FDA
SUBMISSION
FDA
CLEARANCE
ACCURATE DETECTION
Logo for T-Detect
SIGNAL
DISCOVERY
GI Diseases (Celiac, Crohn’s)
Ovarian Cancer
CLINICAL
VALIDATION
FDA
SUBMISSION
FDA
CLEARANCE
(EUA)2
Drug Discovery
EARLY
DEVELOPMENT
IND
SUBMISSION
CLINICAL
DEVELOPMENT
TCR-BASED CELL THERAPIES3
Logo for TruTCR
EARLY
DEVELOPMENT
1st Shared
2nd Shared
Personalized
IND
SUBMISSION
CLINICAL
DEVELOPMENT
NEUTRALIZING ANTIBODIES4
Logo for TruAB
COVID-19

1. Available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.

2. This product has received Emergency Use Authorization and is not FDA cleared or approved.

3. Product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The “1st Shared” and “2nd Shared” product candidates refer to the two lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to, the FDA.

4. Product candidates in development.

STAY IN TOUCH

Receive the latest

Adaptive news and updates

Your email is safe with us. Read our Privacy Policy.